The National Cancer Center of Japan, in collaboration with Toray Group, has developed a technology that can screen for 13 types of cancer, including breast, lung, and stomach cancer, using just a single drop of blood based on the molecular characteristics of microRNA in the blood. Research shows that its average diagnostic accuracy reaches 95%, with breast cancer detection accuracy at 97%. The technology is planned to undergo clinical validation by analyzing the blood of approximately 3,000 participants and is expected to be available on the market within three years. Compared with traditional tumor marker testing, this method can detect abnormalities at an earlier stage of cancer, significantly reducing screening costs and physical burden, and is expected to become a routine screening tool in health management.